34
Participants
Start Date
March 4, 2016
Primary Completion Date
October 16, 2021
Study Completion Date
January 26, 2024
Cisplatin
The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m\^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
Methotrexate
The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m\^2).
Gemcitabine
The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m\^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
Lung Cancer Symptom Scale for Mesothelioma Questionnaire
Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
H. Lee Moffitt Cancer Center and Research Institute, Tampa
H. Lee Moffitt Cancer Center and Research Institute
OTHER